Trv Gp Vi LLC Purchases New Holdings in Seaport Therapeutics, Inc. $SPTX

Key Points

• Trv Gp Vi LLC acquired 2.06 million Seaport Therapeutics shares in the second quarter, valued at approximately $44.8 million, giving it a 3.85% stake and making SPTX its second-largest portfolio holding.
• Seaport Therapeutics reported a quarterly loss of $1.78 per share, missing the consensus estimate of a $0.71 loss. Analysts expect a full-year loss of approximately $4.60 per share.
• Analyst sentiment is mixed, with five Buy, three Hold, and two Sell ratings; the average rating is “Hold” and the average price target is $38.40, compared with the stock’s recent price of $23.97.

Trv Gp Vi LLC bought a new position in shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,061,222 shares of the company's stock, valued at approximately $44,769,742,000. Seaport Therapeutics comprises approximately 19.3% of Trv Gp Vi LLC's investment portfolio, making the stock its 2nd biggest holding. Trv Gp Vi LLC owned 3.85% of Seaport Therapeutics at the end of the most recent reporting period.

Seaport Therapeutics Stock Down 1.8%

Shares of NASDAQ:SPTX opened at $23.97 on Wednesday. The company's 50 day simple moving average is $20.65. Seaport Therapeutics, Inc. has a 1 year low of $14.85 and a 1 year high of $25.07. The stock has a market cap of $1.28 billion and a price-to-earnings ratio of -1.98.

Seaport Therapeutics (NASDAQ:SPTX - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($1.07). As a group, analysts forecast that Seaport Therapeutics, Inc. will post -4.6 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Seaport Research Partners set a $50.00 target price on shares of Seaport Therapeutics in a report on Wednesday, July 15th. Weiss Ratings started coverage on shares of Seaport Therapeutics in a research note on Tuesday, August 11th. They set a "sell (d+)" rating on the stock. Leerink Partners started coverage on shares of Seaport Therapeutics in a report on Tuesday, May 26th. They set an "outperform" rating and a $35.00 price objective on the stock. Citigroup began coverage on Seaport Therapeutics in a report on Tuesday, May 26th. They set a "buy" rating and a $35.00 target price for the company. Finally, BNP Paribas Exane cut Seaport Therapeutics to a "market perform" rating in a research report on Tuesday, May 26th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $38.40.

Insider Buying and Selling at Seaport Therapeutics

In other news, Director Robert J. Hombach acquired 13,000 shares of the company's stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $18.14 per share, with a total value of $235,820.00. Following the completion of the acquisition, the director owned 13,000 shares of the company's stock, valued at $235,820. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Seaport Therapeutics Profile

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source